159 filings
Page 6 of 8
8-K
tyzd2ux0 75nvq
29 Mar 05
Entry into a Material Definitive Agreement
12:00am
8-K
nkk2byojtsldfcwxcg1
22 Mar 05
Oscient Pharmaceuticals Names Gary Patou, M.D. to Board
12:00am
8-K
a4vhzrs73vlbb66vq
8 Feb 05
Entry into a Material Definitive Agreement
12:00am
8-K
moz1 bbm7hv4xl7lzf39
10 Jan 05
Oscient Pharmaceuticals’ Board of Directors Names 25-Year Lilly Veteran John E. Voris to Board
12:00am
8-K
pxxi9
10 Jan 05
Other Events
12:00am
8-K/A
btl7 vnt98ac
7 Jan 05
Oscient Pharmaceuticals Hires Nick Colangelo as Senior Vice President of Corporate Development and Operations
12:00am
8-K
f84leellq94sh4zv0h
6 Jan 05
Oscient Pharmaceuticals Hires Nick Colangelo as Senior Vice President of Corporate Development and Operations
12:00am
8-K
w3otvwgapf
10 Nov 04
Launch of FACTIVE Tablets Highlights Quarter
12:00am
8-K
nwv2tg8uz
12 Aug 04
Other events
12:00am
8-K
h46rypkx1
10 Aug 04
Oscient Pharmaceuticals Releases Preliminary Results from Phase II
12:00am
8-K
xiln3q 9zu
9 Aug 04
Oscient Pharmaceuticals Reports Financial Results for Second Quarter of 2004
12:00am
8-K
ro69cc gsihq
26 May 04
Oscient Pharmaceuticals Closes Initial Purchasers’ Option for Convertible Notes Offering
12:00am
8-K
5380fecz268rv
14 May 04
Oscient Pharmaceuticals Reports Financial Results for First Quarter of 2004
12:00am
8-K
66c557gk0tp7g1sspx
11 May 04
Oscient Pharmaceuticals Completes $125 Million Convertible Notes Offering
12:00am
8-K
2pjsq8ss pui3yakjx
5 May 04
Oscient Pharmaceuticals Announces Pricing of
12:00am
8-K
cl6ykp3h4q v98
3 May 04
Oscient Pharmaceuticals Proposes $75 Million Convertible Notes Offering
12:00am
8-K/A
ff2f707r94enfl4
16 Apr 04
Report of Independent Auditors
12:00am
8-K
vu7ghq
14 Apr 04
Other events
12:00am
8-K
h93mzb09sqhdu8wo
8 Mar 04
Current report
12:00am
8-K
5xb0fa1tg owh
10 Feb 04
Genome Therapeutics and Genesoft Pharmaceuticals Complete Merger to Form Biopharmaceutical Company Focused on Anti-Infectives
12:00am